ArticleFrontiers in nutrition2025
Effects of oral nutritional supplements plus mature silkworm pill on cognitive function in Korean adults with mild cognitive impairment: a 12-week randomized blinded clinical trial.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to determine whether mature silkworm pills plus commercial oral nutritional supplements (ONS) could improve cognitive function, especially in individuals with mild cognitive impairment (MCI). Methods: A total of 62 participants (70.6 ± 8.5 years, 48.4% female), aged ≥50 years diagnosed with mild cognitive impairment but not dementia, were randomly assigned into the 12-week ONS plus silkworm pill group (30 participants, commercial ONS with mature silkworm pills) or the placebo group (32 participants, placebo ONS containing protein, carbohydrates, and fats, with placebo pills containing dextrin). During the 12-week intervention, participants consumed the allocated pills and ONS once daily. Additionally, nutritional education related to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet therapy and proper eating habits was provided at weeks 0, 3, 6, and 9. The primary outcome was interval change in the Korean version of the Repeatable Battery for the Assessment of Neuropsychological Status (K-RBANS) after the 12-week intervention. Secondary outcomes included interval changes in nutrient intake, nutrition-related blood test results, nutritional quotient, and MIND score evaluation. Results: After 12 weeks, the interval change in the delayed memory domain score of the K-RBANS was improved in the ONS plus silkworm pill group (65.9 ± 19.0 vs. 70.5 ± 19.0, Conclusion: After the 12-week intervention, the ONS and silkworm pill group showed a significant improvement in delayed memory compared with the placebo group. However, no significant differences were observed in other cognitive domains or secondary outcomes, such as nutrient intake, blood test results, nutrition quotient, or MIND score adherence. These findings suggest that, while the combination may have a positive impact on specific cognitive functions, further research is needed to fully understand its potential benefits and mechanisms of action. Clinical Trial Registration: https://trialsearch.who.int/Trial2.aspx?TrialID=KCT0007304.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.